| Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. | |
| | |
MedLine Citation:
|
PMID: 20834185 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Erythropoietin (EPO) enhances re-endothelialization and anti-apoptotic action. Larger clinical studies to examine the effects of high-dose EPO are in progress in patients with acute myocardial infarction (AMI). METHODS AND RESULTS: The aim of this multi-center pilot study was to investigate the effect of `low-dose EPO' (6,000 IU during percutaneous coronary intervention (PCI), 24 h and 48 h) in 35 patients with a first ST-elevated AMI undergoing PCI who was randomly assigned to EPO or placebo (saline) treatment. Neointimal volume, cardiac function and infarct size were examined in the acute phase and 6 months later (ClinicalTrials.gov identifier: NCT00423020). No significant regression in in-stent neointimal volume was observed, whereas left ventricular (LV) ejection fraction was significantly improved (49.2% to 55.7%, P=0.003) and LV end-systolic volume was decreased in the EPO group (47.7 ml to 39.0 ml, P=0.036). LV end-diastolic volume tended to be reduced from 90.2% to 84.5% (P=0.159), whereas in the control group it was inversely increased (91.7% to 93.7%, P=0.385). Infarction sizes were significantly reduced by 38.5% (P=0.003) but not in the control group (23.7%, P=0.051). Hemoglobin, peak creatine kinase values, and CD34(+)/CD133(+)/CD45(dim) endothelial progenitors showed no significant changes. No adverse events were observed during study periods. CONCLUSIONS: This is a first study demonstrating that short-term `low-dose' EPO to PCI-treated AMI patients did not prevent neointimal hyperplasia but rather improved cardiac function and infarct size without any clinical adverse effects. |
| | |
Authors:
|
Norimasa Taniguchi; Takeshi Nakamura; Takahisa Sawada; Kinya Matsubara; Keizo Furukawa; Mitsuyoshi Hadase; Yoshifumi Nakahara; Takashi Nakamura; Hiroaki Matsubara |
Related Documents
:
|
17081085 - Use of the ace inhibitor zofenopril in the treatment of ischemic heart disease. 23139095 - Copeptin in acute chest pain: identification of acute coronary syndrome and obstructive... 19332195 - Aldosterone and long-term outcome after myocardial infarction: a substudy of the french... 9643275 - Absence of a seasonal variation in myocardial infarction onset in a region without temp... 19088445 - Post-conditioning preserves glycolytic atp during early reperfusion: a survival mechani... 16563105 - Aetiology and management of acute cardiac tamponade. |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial Date: 2010-09-08 |
Journal Detail:
|
Title: Circulation journal : official journal of the Japanese Circulation Society Volume: 74 ISSN: 1347-4820 ISO Abbreviation: Circ. J. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-10-29 Completed Date: 2010-11-30 Revised Date: 2011-02-18 |
Medline Journal Info:
|
Nlm Unique ID: 101137683 Medline TA: Circ J Country: Japan |
Other Details:
|
Languages: eng Pagination: 2365-71 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, Sakurakai Takahashi Hospital, Kobe, Japan. |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00423020 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angioplasty, Balloon, Coronary* / adverse effects Biological Markers / blood Cardiovascular Agents / administration & dosage*, adverse effects Chi-Square Distribution Coronary Angiography Coronary Restenosis / diagnosis, etiology, prevention & control* Creatine Kinase / blood Endothelial Cells / drug effects, pathology Erythropoietin, Recombinant / administration & dosage*, adverse effects Female Hemoglobins / metabolism Humans Hyperplasia Japan Male Middle Aged Myocardial Infarction / diagnosis, physiopathology, therapy* Myocardium / pathology Pilot Projects Placebo Effect Prospective Studies Stem Cells / drug effects, pathology Stroke Volume / drug effects Time Factors Treatment Outcome Ultrasonography, Interventional Ventricular Function, Left / drug effects Ventricular Remodeling / drug effects* |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Cardiovascular Agents; 0/Erythropoietin, Recombinant; 0/Hemoglobins; 0/epoetin beta; EC 2.7.3.2/Creatine Kinase |
| Comments/Corrections | |
Comment In:
|
Circ J. 2010 Nov;74(11):2290-2
[PMID:
20962420
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Normalized wall index specific and MRI-based stress analysis of atherosclerotic carotid plaques: a s...
Next Document: Gender differences in the ST segment: effect of androgen-deprivation therapy and possible role of te...